The decrease of JAK2 V617F allele burden in leukemia transformation of an elderly patient with myelofibrosis

Leukemia Research

Volumn 33, Issue 8, 2009, Pages

  Zhang, Su Jiang ^a   Li, Jian Yong ^a   Zhang, Jian Fu ^a   Finn, Jonathan ^b   Lu, Hui ^b   Xu, Wei ^a   Qian, Si Xuan ^a   Wu, Han Xin ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACLARUBICIN; CYTARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; JANUS KINASE 2; PREDNISONE; THALIDOMIDE;

AGED; BONE MARROW BIOPSY; CASE REPORT; DEEP VEIN THROMBOSIS; DISEASE COURSE; DRUG WITHDRAWAL; FLOW CYTOMETRY; GENE MUTATION; HEMODYNAMIC PARAMETERS; HUMAN; IMMUNOMODULATION; LETTER; LEUKEMIA; LOW DRUG DOSE; MALE; MYELOFIBROSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

AGED; ALLELES; HUMANS; JANUS KINASE 2; LEUKEMIA, MYELOID, ACUTE; MALE; MUTATION, MISSENSE; NEOPLASM PROTEINS; PRIMARY MYELOFIBROSIS;

EID: 67349098434     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.02.004     Document Type: Letter

References (17)

1. Kilpivaara O., and Levine R.L. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science. Leukemia 22 (2008) 1813-1817
2. Theocharides A., Boissinot M., Girodon F., et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 110 (2007) 375-379
3. Hsiao H.H., Yang W.C., Liu Y.C., et al. Disappearance of JAK2 V617F mutation in a rapid leukemic transformed essential thrombocythemia patient. Leuk Res 32 (2008) 1323-1324
4. Schneider F., Bohlander S.K., Schneider S., et al. AML1-ETO meets JAK2: clinical evidence for the two hit model of leukemogenesis from a myeloproliferative syndrome progressing to acute myeloid leukemia. Leukemia 21 (2007) 2199-2201
5. Rossi D., Deambrogi C., Capello D., et al. JAK2 V617F mutation in leukaemic transformation of philadelphia-negative chronic myeloproliferative disorders. Br J Haematol 135 (2006) 267-268
6. Wu Y.Y., Hung H.M., Chen T.S., et al. Decreased JAK2 V617F allele burden level in a myelofibrosis with myeloid metaplasia patient with leukemic transformation. Leuk Res 32 (2008) 1783-1786
7. Jamal R., Bélisle C., Lessard M.C., et al. Evidence suggesting the presence of a stem cell clone anteceding the acquisition of the JAK2-V617F mutation. Leukemia 22 (2008) 1472-1474
8. Zhang S., Qiu H., Fischer B.S., et al. JAK2 V617F patients with essential thrombocythemia present with clinical features of polycythemia vera. Leuk Lymphoma 49 (2008) 696-699
9. Qian S.X., Li J.Y., Tian T., et al. Effect of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on the outcome of elderly patients with acute myeloid leukemia. Leuk Res 31 (2007) 1383-1388
10. Barosi G., Bergamaschi G., Marchetti M., et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 110 (2007) 4030-4036
11. Mesa R.A., Powell H., Lasho T., et al. JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia. Leuk Res 30 (2006) 1457-1460
12. Mesa R.A., Verstovsek S., Cervantes F., et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res 31 (2007) 737-740
13. Vicente C., Vázquez I., Marcotegui N., et al. JAK2-V617F activating mutation in acute myeloid leukemia: prognostic impact and association with other molecular markers. Leukemia 21 (2007) 2386-2390
14. Illmer T., Schaich M., Ehninger G., et al. Tyrosine kinase mutations of JAK2 are rare events in AML but influence prognosis of patients with CBF-leukemias. Haematologica 92 (2007) 137-138
15. Schnittger S., Bacher U., Kern W., et al. JAK2 seems to be a typical cooperating mutation in therapy-related t(8;21)/AML1-ETO-positive AML. Leukemia 21 (2007) 183-184
16. Schnittger S., Bacher U., Kern W., et al. JAK2V617F as progression marker in CMPN and as cooperative mutation in AML with trisomy 8 and t(8;21): a comparative study on 1103 CMPN and 269 AML cases. Leukemia 21 (2007) 1843-1845
17. Pasqualucci L., Li S., Meloni G., et al. NPM1-mutated acute myeloid leukaemia occurring in JAK2-V617F+ primary myelofibrosis: de-novo origin?. Leukemia 22 (2008) 1459-1463